Brain tumors are notoriously difficult for most drugs to reach, but Yale Univ. researchers have found a promising but unlikely new ally against brain cancers, portions of a deadly virus similar to Ebola. A virus containing proteins found in the Lassa virus not only passed through the formidable blood-brain barrier but destroyed brain tumors in mice, according to research released in the Journal of Virology.
Nowhere is the adage "form follows function" more true than in the folded chain of amino acids...
The human immune system is poised to spring into action at the first sign of a foreign invader,...
Univ. of Michigan researchers have discovered a biomarker that may be a potentially important...
Researchers have demonstrated a promising new way to increase the effectiveness of radiation in killing cancer cells. The approach involves gold nanoparticles tethered to acid-seeking compounds called pHLIPs. The pHLIPs (pH low-insertion peptides) home in on high acidity of malignant cells, delivering their nanoparticle passengers straight to the cells’ doorsteps.
Scientists are mapping the habits of cancer cells, turn by microscopic turn. Using advanced technology and an approach that merges engineering and medicine, a Yale Univ.-led team has compiled some of the most sophisticated data yet on the elaborate signaling networks directing highly invasive cancer cells. Think of it as a digital field guide for a deadly scourge.
Biologists have discovered a vulnerability of brain cancer cells that could be exploited to develop more-effective drugs against brain tumors. The study found that a subset of glioblastoma tumor cells is dependent on a particular enzyme that breaks down the amino acid glycine. Without this enzyme, toxic metabolic byproducts build up inside the tumor cells, and they die.
Northwestern Medicine scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma mulitforme (GBM), a deadly and incurable type of brain tumor. While standard chemotherapy drugs damage DNA to stop cancer cells from reproducing, the new method stops the source that creates those cancer cells: genes that are overexpressing certain proteins.
Stem cells hold great promise for treating a number of diseases, in part because they have the unique ability to differentiate, specializing into any one of the hundreds of cell types that comprise the human body. Harnessing this potential, though, is difficult.
In the 1970s, epidemiologists found that workers in factories using vinyl chloride had unusually high rates of a rare form of liver cancer called angiosarcoma. Biologists later identified a mutation that appears to be associated with this cancer, which originates in cells of the blood vessels that feed the liver.
Scientists from the Florida campus of The Scripps Research Institute have uncovered the unique mechanism of a powerful natural product with wide-ranging antifungal, antibacterial antimalaria and anticancer effects. The new study sheds light on the natural small molecule known as borrelidin.
An experimental drug rapidly shrinks most tumors in a mouse model of human breast cancer, researchers report in the Proceedings of the National Academy of Sciences. When mice were treated with the experimental drug, BHPI, the tumors immediately stopped growing and began shrinking rapidly.
Imaging tests like mammograms or CT scans can detect tumors, but figuring out whether a growth is or isn't cancer usually requires a biopsy to study cells directly. Now results of a Johns Hopkins Univ. study suggest that MRI could one day make biopsies more effective or even replace them altogether by noninvasively detecting telltale sugar molecules shed by the outer membranes of cancerous cells.
Saccharin, the artificial sweetener that is the main ingredient in Sweet 'N Low, Sweet Twin and Necta, could do far more than just keep our waistlines trim. According to new research, this popular sugar substitute could potentially lead to the development of drugs capable of combating aggressive, difficult-to-treat cancers with fewer side effects.
The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study co-authored by an Massachusetts Institute of Technology economist. But the exact reasons for the cost increases are unclear. Since 1995, a group of 58 leading cancer drugs has increased in price by 10% annually, even when adjusted for inflation and incremental health benefits, the study finds.
Cancer cells crowded tightly together suddenly surrender their desire to spread, and this change of heart is related to a cellular pathway that controls organ size. These two observations are reported by researchers at Georgetown Lombardi Comprehensive Cancer Center in Oncogene.
Scientists from Lawrence Berkeley National Laboratory have uncovered new clues about the risk of cancer from low-dose radiation, which in this research they define as equivalent to 100 millisieverts or roughly the dose received from ten full-body CT scans. They studied mice and found their risk of mammary cancer from low-dose radiation depends a great deal on their genetic makeup.
An extraordinary self-regulating heating effect that can be achieved in a particular type of magnetic material may open the doors to a new strategy for hyperthermia cancer treatment. Temperatures that can be tolerated by healthy body cells have long been known to destroy cancerous cells. An approach that uses magnetic particles introduced into tissue and heated remotely has found some success in treating cancer.
Chemotherapy often shrinks tumors at first, but as cancer cells become resistant to drug treatment, tumors can grow back. A new nanodevice developed by Massachusetts Institute of Technology researchers can help overcome that by first blocking the gene that confers drug resistance, then launching a new chemotherapy attack against the disarmed tumors.
A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.
Univ. of Manchester scientists have used graphene to target and neutralize cancer stem cells while not harming other cells. This new development opens up the possibility of preventing or treating a broad range of cancers, using a non-toxic material.
A protein found in pancreatic tumors may lead to a new chemotherapy that is effective against many different kinds of cancers, but turning the discovery into a new drug has required a bit of chemistry know-how.
In recent years, scientists have found a surprising a connection between some people with autism and certain cancer patients: They have mutations in the same gene, one that codes for a protein critical for normal cellular health. Now scientists have reported in Biochemistry that the defects reduce the activity and stability of the protein. Their findings could someday help lead to new treatments for both sets of patients.
Single-letter genetic variations within parts of the genome once dismissed as 'junk DNA' can increase cancer risk through wormhole-like effects on far-off genes, new research shows.
Scientists have shown that gold nanotubes have many applications in fighting cancer: internal nanoprobes for high-resolution imaging, drug delivery vehicles and agents for destroying cancer cells. The study, published in Advanced Functional Materials, details the first successful demonstration of the biomedical use of gold nanotubes in a mouse model of human cancer.
Applying lessons learned from autism to brain cancer, researchers at The Johns Hopkins Univ. have discovered why elevated levels of the protein NHE9 add to the lethality of the most common and aggressive form of brain cancer, glioblastoma. Their discovery suggests that drugs designed to target NHE9 could help to successfully fight the deadly disease.
Federal health regulators on Tuesday approved a highly anticipated medicine from Pfizer Inc. to treat postmenopausal women with a certain type of advanced breast cancer who have not already taken other drugs. The Food and Drug Administration approved Ibrance for women who have tumors that do not contain a protein known as HER-2. Ibrance, known generically as palbociclib, works by blocking molecules linked to cancer cell growth.
Low doses of metformin, a widely used diabetes medication and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue Univ. study finds. Prostate cancer causes the second-highest number of cancer-related deaths in men in the U.S., and methods of treating advanced prostate cancer are limited.
A new study by Univ. of Kentucky Markey Cancer Center researchers suggests that targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat lung cancer. Cancer cells undergo metabolic alterations to meet the increased energy demands that support their excess growth and survival.
- Page 1